UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

Annals of oncology, 2018-03, Vol.29 (3), p.766-771

2018

Volltextzugriff (PDF)

Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?

Annals of oncology, 2018-10, Vol.29, p.viii713-viii713

2018

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-11, Vol.29, p.ix23-ix23

2018

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii133

2018

Volltextzugriff (PDF)

277 INVITED IGF1R Targeting in Non-sarcoma Pediatric Malignancies

European journal of cancer (1990), 2011, Vol.47, p.S64-S65

Geoerger, B

2011

Volltextzugriff (PDF)

Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii142

2018

Volltextzugriff (PDF)

Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

European journal of cancer (1990), 2016-12, Vol.69, p.S49-S50

2016

Volltextzugriff (PDF)

347 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro

European journal of cancer (1990), 2012-11, Vol.48, p.106-106

2012

Volltextzugriff (PDF)

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

Annals of oncology, 2015-02, Vol.26 (2), p.422-428

2015

Volltextzugriff (PDF)

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

British journal of cancer, 2003-08, Vol.89 (3), p.577-584

2003

Volltextzugriff (PDF)

Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework

Contemporary clinical trials, 2012-07, Vol.33 (4), p.657-665

2012

Volltextzugriff (PDF)

253 Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies

European journal of cancer (1990), 2012-11, Vol.48, p.78-78

2012

Volltextzugriff (PDF)

9 INVITED Targeted therapies for paediatric brain tumours

European journal of cancer supplements, 2007, Vol.5 (4), p.6-6

Geoerger, B

2007

Volltextzugriff (PDF)

205 Development of Metastasis Following Inhibition of VEGFR Pathway in an Orthotopic Neuroblastoma Model

European journal of cancer (1990), 2012-11, Vol.48, p.62-62

2012

Volltextzugriff (PDF)

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation

Nature Medicine, 2023-06, Vol.29 (6), p.1358-1363

2023

Volltextzugriff (PDF)

Innovative Therapies for Children with Cancer (ITCC): Clinical Trial Program

Klinische Pädiatrie, 2011-01, Vol.223 (1)

2011

Volltextzugriff (PDF)

Precision cancer medicine: Concepts, current practice, and future developments

Journal of internal medicine, 2023-10, Vol.294 (4), p.455-481

2023

Volltextzugriff (PDF)

424P_PRInclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Annals of oncology, 2022-09, Vol.33, p.S751-S752

2022

Volltextzugriff (PDF)

Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan

Oncogene, 2006-05, Vol.25 (22), p.3150-3159

2006

Volltextzugriff (PDF)

019 - BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL

Leukemia research, 2022-10, Vol.121, p.S16-S17

2022

Volltextzugriff (PDF)

BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL

Leukemia research, 2022-10, Vol.121, p.S16-S17

2022

Volltextzugriff (PDF)

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

The journal of gene medicine, 2005-05, Vol.7 (5), p.584-594

2005

Volltextzugriff (PDF)

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma

Neuro-oncology (Charlottesville, Va.), 2015-07, Vol.17 (7), p.953-964

2015

Volltextzugriff (PDF)

464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset

Annals of oncology, 2022-09, Vol.33, p.S752-S753

2022

Volltextzugriff (PDF)

1 – 25 von 287

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(258)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(36)
Humans
(34)
Oncology
(28)
Child
(21)
Female
(17)
Biological And Medical Sciences
(15)
Hematology, Oncology And Palliative Medicine
(15)
Medical Sciences
(15)
Tumors
(13)
Life Sciences
(12)
Male
(12)
Child, Preschool
(11)
Adolescent
(10)
Pediatrics
(10)
Animals
(8)
Neuroblastoma
(8)
Infant
(7)
Medicin Och Hälsovetenskap
(7)
Mice
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

277 INVITED IGF1R Targeting in Non-sarcoma Pediatric Malignancies

Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program

Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

347 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework

253 Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies

9 INVITED Targeted therapies for paediatric brain tumours

205 Development of Metastasis Following Inhibition of VEGFR Pathway in an Orthotopic Neuroblastoma Model

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation

Innovative Therapies for Children with Cancer (ITCC): Clinical Trial Program

Precision cancer medicine: Concepts, current practice, and future developments

424P_PRInclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth?

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan

019 - BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL

BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma

464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset

Suchergebnisse filtern